Bryn Mawr Trust Advisors LLC Has $19.01 Million Stake in Merck & Co., Inc. $MRK

Bryn Mawr Trust Advisors LLC trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 1.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 240,079 shares of the company’s stock after selling 2,982 shares during the period. Merck & Co., Inc. comprises about 1.0% of Bryn Mawr Trust Advisors LLC’s investment portfolio, making the stock its 17th largest position. Bryn Mawr Trust Advisors LLC’s holdings in Merck & Co., Inc. were worth $19,005,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the last quarter. Linden Thomas Advisory Services LLC boosted its holdings in shares of Merck & Co., Inc. by 6.6% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 11,659 shares of the company’s stock worth $1,047,000 after acquiring an additional 726 shares in the last quarter. Forza Wealth Management LLC raised its position in Merck & Co., Inc. by 1.3% in the 1st quarter. Forza Wealth Management LLC now owns 10,761 shares of the company’s stock valued at $966,000 after purchasing an additional 138 shares during the last quarter. Rogco LP boosted its stake in Merck & Co., Inc. by 4.2% in the first quarter. Rogco LP now owns 8,446 shares of the company’s stock worth $758,000 after purchasing an additional 342 shares in the last quarter. Finally, tru Independence LLC grew its holdings in shares of Merck & Co., Inc. by 4.9% during the first quarter. tru Independence LLC now owns 50,977 shares of the company’s stock worth $4,576,000 after purchasing an additional 2,374 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on MRK shares. Morgan Stanley lifted their price target on Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company dropped their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $104.47.

Insider Activity

In other news, EVP David Michael Williams sold 8,614 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total value of $720,044.26. Following the completion of the sale, the executive vice president directly owned 24,578 shares of the company’s stock, valued at $2,054,475.02. This represents a 25.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $85.90 on Friday. The firm’s 50 day moving average price is $84.55 and its two-hundred day moving average price is $81.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $105.07. The stock has a market cap of $214.56 billion, a PE ratio of 13.24, a PEG ratio of 0.95 and a beta of 0.34.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. During the same quarter in the prior year, the business posted $1.57 EPS. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.